02:35 , Feb 26, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bladder cancer; breast cancer; colorectal cancer; melanoma; sarcoma Mouse studies suggest inhibiting DDR2 could enhance the efficacy of anti-PD-1 therapies for bladder, breast and colorectal cancers, melanoma and sarcoma. In mouse models of bladder...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed on Jan. 3 to acquire the bellwether for $74 billion....
14:08 , Jan 3, 2019 |  BC Extra  |  Company News

New Year splash as BMS to acquire Celgene in $74B deal

The biggest biotech takeout in a decade brings a tumultuous 15 months for Celgene Corp. (NASDAQ:CELG) to an end as Bristol-Myers Squibb Co. (NYSE:BMY) proposed Thursday to acquire the bellwether for $74 billion. BMS cited...
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
02:50 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

Rethinking definitions of autoimmune disease

The autoimmune field is dialing up its search for better biomarkers as it seeks to make the next step change from the targeted therapies that overtook blanket immunosuppressants. The question is whether autoimmunity might follow...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A heterocycloalkynylbenzimide-based dual DDR1/DDR2 inhibitor could be used to probe the role of two proteins in inflammatory diseases. Chemical synthesis and in vitro activity assays of heterocycloalkynylbenzimide analogs identified a compound that...
22:41 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

Higher doses of BMS's psoriasis candidate hit Phase II efficacy mark

Bristol-Myers Squibb Co. (NYSE:BMY) said four of five doses of BMS-986165 met the primary endpoint in the Phase II IM011-011 trial to treat moderate to severe plaque psoriasis. The compound, an oral tyrosine kinase 2...